Stimulating the brain's immune response may provide treatment for Alzheimer's disease

Jan 26, 2011

A new target for the prevention of adverse immune responses identified as factors in the development of Alzheimer's disease (AD) has been discovered by researchers at the University of South Florida's Department of Psychiatry and the Center of Excellence for Aging and Brain Repair.

Their findings are published online in the Journal of Neuroscience.

The CD45 molecule is a receptor on the surface of the brain's microglia cells, cells that support the brain's and also participate in brain immune responses.

Previous studies by the USF researchers showed that triggering CD45 was beneficial because it blocked a very early step in the development of Alzheimer's disease. In the present study, the researchers demonstrated in Alzheimer's mouse models that a loss of CD45 led to dramatically increased microglial inflammation.

Although the brain's is involved in Alzheimer's disease pathology, "this finding suggests that CD45 on brain appears critically involved in dampening harmful inflammation," said study senior author Jun Tan, MD, PhD, a professor of psychiatry and Robert A. Silver chair at the Rashid Laboratory for Developmental Neurobiology, USF Silver Child Development Center and research biologist for Research and Development Service at the James A. Haley Veteran's Hospital.

The investigators also found an increase in harmful , such as A beta , as well as neuron loss in the brains of the test mice.

"In short, CD45 deficiency leads to increased accumulation of neurotoxic A beta in the brains of old Alzheimer's mice, demonstrating the involvement of CD45 in clearing those toxins and protecting neurons," Dr. Tan said. "These findings are quite significant, because many in the field have long considered CD45 to be an indicator of harmful . So, researchers assumed that CD45 was part of the problem, not a potential protective factor."

The next step is to apply these findings to develop new Alzheimer's disease treatments, said Paula Bickford, PhD, a professor in the USF Department of Neurosurgery and senior career research scientist at the James A. Haley Veteran's Hospital.

"We are already working with Natura Therapeutics, Inc. to screen for natural compounds that will target CD45 activation in the brain's immune cells," Dr. Bickford said.

Explore further: Tackling neurotransmission precision

More information: http://www.jneurosci.org/

Provided by University of South Florida

4.5 /5 (2 votes)
add to favorites email to friend print save as pdf

Related Stories

Team studies T cell activation with nanoparticles

Apr 28, 2010

A University of Alberta-led research team has taken a major step forward in understanding how T cells are activated in the course of an immune response by combining nanotechnology and cell biology. T cells are the all important ...

Recommended for you

Tackling neurotransmission precision

5 hours ago

Behind all motor, sensory and memory functions, calcium ions are in the brain, making those functions possible. Yet neuroscientists do not entirely understand how fast calcium ions reach their targets inside ...

What makes kids generous? Neuroscience has some answers

5 hours ago

It's no secret that people are judgmental, and young children are no exception. When children witness "good" or "bad" behavior, their brains show an immediate emotional response. But, according to a study ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.